Targets

We have introduced new management targets covering environmental, social and governance (ESG) topics, in alignment with our company-level priority of building trust with society. The topics covered include environmental sustainability, pricing and access to medicines, global health challenges, ethics, risk and compliance.
Pricing and access
Global health challenges

Advance clinical development program for our next-generation antimalarials, KAE609 and KAF156.

Learn more about our ongoing efforts against malaria

Expand Africa Sickle Cell Disease program rollout to five countries by end of 2020 and to 10 countries by 2022.

Learn more about our ongoing efforts to fight sickle cell disease

Advance clinical development program for our heart failure medicine in patients with Chagas-related heart failure

Learn more about our ongoing efforts against Chagas disease

Ethics, risk and compliance

100% of clinical trial results posted on either clinicaltrials.gov or novartisclinicaltrials.com within one year of completion

Learn more about our approach to clinical trial transparency

  • Third-party risk assessment conducted for 100% all new eligible suppliers
  • Complete risk assessments of existing suppliers by 2022
  • Fully integrate human. rights into third-party risk assessments in scope

Learn more about our approach to third-party risk management

Responsible citizenship
  • 2025: Be carbon neutral in our own operations (Scope 1 and 2); Include environmental criteria in all supplier contracts
  • 2030: achieve full carbon neutrality across the supply chain (Scope 1, 2, 3)

Learn more about our efforts to reduce our impacts on climate

  • 2025: reduce water consumption in our operations by half versus 2016 baseline, with no water quality impacts from manufacturing effluents
  • 2030: be water neutral in all areas of our operations, while actively enhancing water quality wherever we operate

Learn more about our efforts to reduce our impacts on water

  • 2025: eliminate polyvinyl chloride (PVC) in packaging (secondary and tertiary packaging; primary packaging when feasible) and reduce waste disposal by half versus 2016 levels 
  • 2030: be plastic neutral, with all new products meeting sustainable design principles 

Learn more about our efforts to reduce our impacts on waste

  • Achieve gender balance in management by 2023
  • Close the gender pay gap by 2023

Learn more about Diversity & Inclusion at Novartis

  • Invest USD 100m in learning over the next five years from 2019

Results

Explore our Novartis in Society ESG report to see how we performed in 2020.

Learn more about our approach to ESG topics